XML 48 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Composition of Balance Sheet Items (Tables)
 9 Months Ended
Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of inventories
Inventories
September 30,
2021		December 31,
2020
(unaudited)
Raw materials$9,710 $22,208 
Work in process37,910 8,985 
Finished goods12,535 17,132 
Total$60,155 $48,325 
Schedule of property and equipment
Property and Equipment
September 30,
2021		December 31,
2020
(unaudited)
Lab equipment and furniture$11,734 $12,526 
Leasehold improvements12,453 15,183 
Software2,023 2,295 
Finance lease assets (1)
— 22,747 
Computer equipment1,156 2,113 
Construction-in-progress209 — 
27,575 54,864 
Less accumulated depreciation and amortization(11,104)(17,040)
Total$16,471 $37,824 
_______________________________
(1) Refer to Note 12, Leases.
Schedule of accounts payable and accrued liabilities
Accounts Payable and Accrued Liabilities
September 30,
2021		December 31,
2020
(unaudited)
Accounts payable$9,125 $6,147 
Accrued compensation13,426 16,008 
Accrued royalties (1)
12,781 13,890 
Accrued product costs8,408 9,587 
Accrued professional fees7,453 7,730 
Accrued clinical trial costs (2)
6,774 12,842 
Operating lease liabilities, current portion (3)
5,904 3,760 
Other accrued expenses8,415 8,970 
Total$72,286 $78,934 
_______________________________
(1) Refer to Note 15, Commitments and Contingencies.
(2) Includes preclinical and all clinical trial-related costs.
(3) Refer to Note 12, Leases.
Schedule of accrued product returns and rebates
Accrued Product Returns and Rebates
September 30,
2021		December 31,
2020
(unaudited)
Accrued product rebates$98,636 $96,589 
Accrued product returns33,412 29,603 
Total$132,048 $126,192 
Other liabilities
Other Liabilities
September 30,
2021		December 31,
2020
 (unaudited)
Nonrecourse liability related to sale of future royalties, long term$8,139 $13,410 
Finance lease liability, long term (1)
— 20,235 
Other liabilities10,047 9,146 
Total$18,186 $42,791 
______________________________
(1) Refer to Note 12, Leases.